Atlas is an international venture capital firm that invests primarily in early stage technology and life sciences businesses in the U.S. and Europe. Atlas Venture typically is the lead investor, and the firm prefers to take significant stakes in seed and early-stage businesses. They will also invest in late-stage opportunities. A typical investment for Atlas Venture ranges from $5 million to $25 million over the life of the company.
In Atlas Venture's technology practice, their team looks for businesses in components, systems, software, and services. In their life sciences practice, their team looks for companies in pharmaceuti...
More >>
Atlas is an international venture capital firm that invests primarily in early stage technology and life sciences businesses in the U.S. and Europe. Atlas Venture typically is the lead investor, and the firm prefers to take significant stakes in seed and early-stage businesses. They will also invest in late-stage opportunities. A typical investment for Atlas Venture ranges from $5 million to $25 million over the life of the company.
In Atlas Venture's technology practice, their team looks for businesses in components, systems, software, and services. In their life sciences practice, their team looks for companies in pharmaceuticals, drug discovery and medical devices.
<< Less
ARCA biopharma, Inc. is a biopharmaceutical company developing genetically-targeted therapies for heart failure and other cardiovascular diseases. ARCA began operations in 2005 and is headquartered in Denver, Colorado.
Archemix Corp. is a drug discovery and development company based in Cambridge, Mass. Founded in May 2001, the company's mission is to discover aptamer-based therapeutics and to develop RiboReporter„-based technologies to improve the process of drug discovery and development. Both of these technologies derive from Archemix's selected nucleic acid technology.
Aureon Laboratories is a life science company founded in 2002, dedicated to enabling the advancement of predictive and personalized cancer treatment options. Aureon employs a Systems Pathology approach and provides personalized test results by analyzing a patient's existing biopsy sample using molecular diagnostics, sophisticated tissue-based image analysis and advanc...
More >>
Aureon Laboratories is a life science company founded in 2002, dedicated to enabling the advancement of predictive and personalized cancer treatment options. Aureon employs a Systems Pathology approach and provides personalized test results by analyzing a patient's existing biopsy sample using molecular diagnostics, sophisticated tissue-based image analysis and advanced mathematics. The resulting information is objective, predictive and personalized and allows the patient and his doctor to make more-informed treatment decisions.nnAureon's technology fits smoothly with existing clinical and pathological processes. Aureon examines formalin-fixed, paraffin-embedded (FFPE) specimens that are routinely obtained as tissue biopsies. Many existing methods need to destroy the tissue architecture to extract protein or genetic biomarkers, losing critical biological information in the process. Vitally important, Aureon's approach retains the biological information embedded in the patient's tissue resulting in improved test performance.nnIn addition to our clinical tests, Aureon also collaborates with bio-pharmaceutical partners to apply our platform to drug discovery and clinical development. Although our initial research focus has been on prostate cancer, we have completed pilot projects in other cancer areas and we are interested in working with partners in the areas of non-small cell lung cancer (NSCLC), breast cancer, bladder cancer, and colorectal cancer.nnAureon is a founding member of the 21st Century Medicine Coalition, a member of the Personalized Medicine Coalition, and a member of the American Clinical Laboratory Association (ACLA).nnAureon was co-founded by leading physician-scientists at Memorial Sloan-Kettering Cancer Center, Yale Cancer Center, and Albert Einstein College of Medicine.
<< Less
The Myvu Corporation, a privately held company based in Westwood, Massachusetts, is a supplier of eyewear viewers for the portable electronics industry. Myvu's research team has developed a range of highly ergonomic eyewear products.
miRagen Therapeutics, Inc., was founded in 2007 to develop innovative microRNA based therapeutics for cardiovascular and muscle disease. Only recently discovered, miRNAs are short, single-stranded RNA molecules encoded in the genome that regulate gene expression and play a vital role in influencing the pathways responsible for cardiovascular and muscle disease.
Novexel S.A. is a pharmaceutical company focused on the discovery and development of antibacterial and antifungal agents to treat severe and difficult-to-treat infections. Several compounds per the company are in clinical development.
This page is accessible to a membership level higher than you. To improve your membership level you can try the following:
Review More Companies
Complete your profile
Improve your fanbase
Add/Edit more companies
Send a request to site admin at membership@chubbybrain.com requesting to upgrade your membership level. If your profile is eligible, your membership level will be upgraded and you will be notified.
Why can I not access this page?
This page is accessible to a membership level higher than you. To improve your membership level you can try the following:
Review More Companies
Complete your profile
Improve your fanbase
Add/Edit more companies
Send a request to site admin at membership@chubbybrain.com requesting to upgrade your membership level. If your profile is eligible, your membership level will be upgraded and you will be notified.
9,812 Investors 
